My legal research combines my experience as a healthcare attorney with my interest in how pharmaceutical manufacturers’ business strategies and practices influence the public’s access to healthcare. To date, my research has explored these practices in the following areas:
- brand name manufacturers’ manipulation of citizen petitions to delay the entry of generic drugs into the market;
- pharmaceutical practices that exploit less robust informed consent protections afforded human subjects enrolled in clinical trials in developing countries;
- FDA prohibitions on generic manufacturers to change inadequately labelled pharmaceutical products;
- the effectiveness of the compulsory licenses under the DOHA Declaration in terms of developing countries access to essential medicines; and
- economic and regulatory factors influencing the current shortage in generic sterile injectables.